465 related articles for article (PubMed ID: 20172036)
1. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
3. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
5. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
7. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Yu Z; Klaasse E; Heitman LH; Ijzerman AP
Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
Walker BD; Singleton CB; Bursill JA; Wyse KR; Valenzuela SM; Qiu MR; Breit SN; Campbell TJ
Br J Pharmacol; 1999 Sep; 128(2):444-50. PubMed ID: 10510456
[TBL] [Abstract][Full Text] [Related]
9. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
[TBL] [Abstract][Full Text] [Related]
10. Observations on conducting whole-cell patch clamping of the hERG cardiac K
Kang J; Luo Y; Searles M; Rampe D
J Appl Toxicol; 2017 Apr; 37(4):445-453. PubMed ID: 27553911
[TBL] [Abstract][Full Text] [Related]
11. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
12. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Orvos P; Kohajda Z; Szlovák J; Gazdag P; Árpádffy-Lovas T; Tóth D; Geramipour A; Tálosi L; Jost N; Varró A; Virág L
Toxicol Sci; 2019 Apr; 168(2):365-380. PubMed ID: 30561737
[TBL] [Abstract][Full Text] [Related]
14. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
16. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
[TBL] [Abstract][Full Text] [Related]
17. Assessment of temperature-induced hERG channel blockade variation by drugs.
Kauthale RR; Dadarkar SS; Husain R; Karande VV; Gatne MM
J Appl Toxicol; 2015 Jul; 35(7):799-805. PubMed ID: 25348819
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
19. F463L increases the potential of dofetilide on human ether-a-go-go-related gene (hERG) channels.
Cheng G; Wu J; Han W; Sun C
Microsc Res Tech; 2018 Jun; 81(6):663-668. PubMed ID: 29573040
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
Chaudhary KW; O'Neal JM; Mo ZL; Fermini B; Gallavan RH; Bahinski A
Assay Drug Dev Technol; 2006 Feb; 4(1):73-82. PubMed ID: 16506891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
